GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-12	NT$22.85	-0.22%	90,393
26-08-11	NT$22.90	-0.22%	123,870
26-08-10	NT$22.95	-0.22%	111,859
26-08-07	NT$23.00	-1.08%	81,414
26-08-06	NT$23.25	+1.75%	130,448

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Taipei Exchange 2026-08-12			5-day change	1st Jan Change
22.85 ^TWD	-0.22%		0.00%	-11.26%

Aug. 02	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI
Jun. 10	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI

Market Cap	2.57B 79.73M 69.08M 64.72M 59.03M 111M 7.6B 113M 761M 298M 3.81B 299M 293M 12.7B	P/E 2024	-11.8x	P/E 2025	-11.9x
Enterprise Value	2.35B 72.91M 63.17M 59.19M 53.99M 101M 6.95B 103M 696M 272M 3.48B 274M 268M 11.61B	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	79.89%	Yield 2024 *	-	Yield 2025	-

Aug. 02	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI
Jun. 10	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
May. 14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 14	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
Mar. 23	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
Mar. 13	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Dec. 08	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
Nov. 24	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
Nov. 14	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-29	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
25-10-29	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
25-08-13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-12	GlycoNex, Inc. Announces Publication of Preclinical Study on Gnx1021, A Novel Glycan-Targeted Adc for Gastric Cancer	CI

1 day	-0.22%
Current month	+2.70%
1 month	-9.33%
3 months	+1.56%
6 months	-12.28%
Current year	-11.26%

GlycoNex Incorporation Stock

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news : GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Course Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	22.65	23.5
1 month	21.25	24.7
Current year	21.25	30
1 year	20.55	30
3 years	15.6	31.85
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	2018-12-31
Dih Fen Wu DFI	Director of Finance/CFO	-	2009-12-31
Yao Hua Lue IRC	Investor Relations Contact	-	2012-11-11

Director	Title	Age	Since
Tong Hsuan Chang CHM	Chairman	-	2001-01-31
Kao Chung Tsai BRD	Director/Board Member	64	-
Ling-Chun Tsai BRD	Director/Board Member	-	2012-05-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	-0.22%	0.00%	-1.93%	-21.21%	79.73M
LONZA GROUP AG	+0.64%	+0.74%	+3.67%	+15.50%	48.72B
REVOLUTION MEDICINES, INC.	-0.14%	+4.03%	+482.13%	+584.43%	43.99B
BEONE MEDICINES AG	-0.06%	+9.62%	+24.63%	+81.63%	40.82B
IQVIA HOLDINGS INC.	-0.87%	+2.40%	+30.01%	+9.95%	39.79B
CELLTRION, INC.	-4.04%	+6.15%	+23.03%	+48.00%	32.7B
MEDPACE HOLDINGS, INC.	-1.41%	+1.57%	+29.98%	+123.68%	16.66B
ASCENDIS PHARMA A/S	+0.35%	+4.61%	-	-	16.84B
EUROFINS SCIENTIFIC SE	+0.86%	+0.40%	+5.03%	+21.68%	13.95B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.84%	+9.07%	+86.17%	+32.60%	13.58B
Average	-0.42%	+3.39%	+75.86%	+99.58%	26.71B
Weighted average by Cap.	-0.53%	+3.93%	+104.21%	+138.12%

	2024	2025
Net sales	14.7M 456K 395K 370K 338K 635K 43.48M 644K 4.35M 1.7M 21.77M 1.71M 1.67M 72.59M	37.86M 1.17M 1.02M 953K 869K 1.63M 112M 1.66M 11.21M 4.38M 56.07M 4.41M 4.31M 187M
Net income	-230M -7.12M -6.17M -5.78M -5.27M -9.92M -679M -10.07M -68.01M -26.58M -340M -26.74M -26.16M -1.13B	-235M -7.29M -6.32M -5.92M -5.4M -10.15M -696M -10.31M -69.64M -27.22M -348M -27.39M -26.79M -1.16B
Net Debt	-442M -13.71M -11.88M -11.13M -10.15M -19.08M -1.31B -19.38M -131M -51.16M -655M -51.47M -50.35M -2.18B	-220M -6.81M -5.9M -5.53M -5.04M -9.48M -650M -9.63M -65.04M -25.43M -325M -25.58M -25.02M -1.08B